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formance.   Conclusions:   Among those with MCI, TT  3   was 
  associated with a neuropsychological profile typical of pro-
dromal Alzheimer’s disease. While the mechanisms remain 
unclear, optimal levels of thyroid hormone under a compro-
mising condition such as MCI and related neuropathology 
need reconsideration.    Copyright © 2010 S. Karger AG, Basel 
 Introduction 
  Age-associated cognitive decline is paralleled by de-
clines in hormones comprising the major endocrine 
axes, which include the somatotropic, gonadotropic and 
thyrotropic axes   [1–5]  . Data suggest that these declines 
may be more accentuated or accelerated in individuals 
who develop dementia. Subsequently, individuals with 
d e m e n t i a  t e n d  t o  e x h i b i t  l o w e r  l e v e l s  o f  i n s u l i n - l i k e  
growth factor 1 (IGF-1), estrogen, testosterone and thy-
roid hormone (TH) compared to those without dementia 
  [6–8]  . Lower levels of these hormones have also been as-
sociated with future dementia risk   [9, 10]  . Further com-
plicating the picture is that while this general decline is 
observed across most endocrine axes, hypothalamic-pi-
tuitary-adrenal axis activity tends to increase   [11] .  In
Alzheimer’s disease (AD) and mild cognitive impair-
ment (MCI), higher levels of cortisol have been reported 
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 Abstract 
  Background:  Alterations in interrelated endocrine axes may 
be related to the pathogenesis of mild cognitive impairment 
(MCI) and dementia.   Methods:   Salivary cortisol before and 
after a 0.5-mg dexamethasone test, and serum levels of thy-
roid-stimulating hormone, total thyroxine (T  4  ), free T  4 ,  total 
triiodothyronine (TT  3  ), estradiol, testosterone and insulin-
like growth factor 1 were measured in 43 MCI cases and 26 
healthy controls. All participants underwent a comprehen-
sive neuropsychological test battery covering the cognitive 
domains of speed/attention, memory, visuospatial func-
tions, language and executive functions.   Results:   The MCI 
group did not differ in basal levels of endocrine markers 
compared to controls. Among those with MCI, TT  3   levels 
were inversely associated with cognitive performance across 
all domains. After stratifying MCI cases according to TT  3   lev-
els, those with relatively high TT  3  levels showed impairment 
in memory as well as in visuospatial and executive functions. 
Those with TT  3   levels at or below the lower boundary of the 
normal range performed comparably to healthy controls. 
Other endocrine markers were not related to cognitive per-
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and associated with cognitive impairment and progres-
sion of the disease   [12–14] . 
    Experimental evidence relating endocrine axes to AD 
pathology is supportive of the aforementioned observa-
tions. IGF-1 and sex steroid hormones increase clearance 
of the neurotoxic    -amyloid  (A   ) protein   [15, 16]   and 
may slow down disease progression. They also decrease 
hyperphosphorylation of the tau protein, which accumu-
lates in neurofibrillary tangles   [17, 18]   and is associated 
with cognitive impairment   [19]  . TH have been observed 
to decrease amyloid precursor protein expression   [20] , 
and estrogen may prevent A     accumulation through ef-
fects on amyloid precursor protein processing   [21] .  Cor-
tisol, in contrast, has been shown to increase levels of 
A    40   and A    42   and accelerate the development of neuro-
fibrillary tangles in the brain   [22]  . Additionally, cortisol 
generates oxidative stress and excitotoxicity and may 
thereby accelerate atrophy in dementia   [23] . 
    While experimental models are useful to explore un-
derlying mechanisms of hormonal action, they are limited 
for understanding the efficacy of specific hormone levels 
and the timing of hormonal exposures, whether endoge-
nous or exogenous. In humans, higher free thyroxine (fT  4 ) 
levels within the normal range have been linked to in-
creased risk of dementia and higher count of neurofibril-
lary tangles and neuritic plaques 4 years before dementia 
diagnosis   [24]  . In addition, despite potentially beneficial 
and protective effects of sex steroid hormone substitution 
  [25–27]  , major clinical trials have suggested an increased 
risk for dementia and MCI for women on hormone re-
placement therapy  [28] . Clinical trials and  epidemiological 
findings may be contradictory because beneficial versus 
adverse effects may depend on the age and/or stage of dis-
ease, as well as on the temporal relationship between hor-
mone measurements and the clinical course of the disease.
  There is insufficient knowledge regarding the relation-
ship between hormones and cognitive function in MCI, 
the classically defined prodromal stage of dementia. MCI 
is a state of risk for clinical dementia defined by cognitive 
decline greater than expected for ‘normal’ aging but pre-
served activities of daily life  [29] . Understanding hormon-
al interrelationships in MCI provides opportunities for 
earlier interventions in dementia. Since the endocrine 
axes form a closely related, functional system, this study 
aims to examine cortisol, IGF-1, sex steroid hormones and 
TH (i) in MCI subjects compared to healthy controls, (ii) 
in relationship to each other, and (iii) in    relationship    to    
cognitive    function    in    MCI    utilizing    a comprehensive 
neuropsychological test battery. The Gothenburg MCI 
study   [30]   forms the basis for these analyses.
  Subjects  and  Methods 
 Participants 
  MCI cases and healthy controls participating in the Gothen-
burg MCI study  [30]  comprise the sample for these analyses. Data 
were obtained from the first visit of the participants to the mem-
ory clinic at Sahlgrenska University Hospital, Mölndal, Sweden. 
In total, 43 cases with MCI and 26 healthy controls were included. 
MCI cases included in these analyses had a higher mean MMSE 
score (28.1) compared to all cases included in the Gothenburg 
MCI study (26.6), but did not differ in terms of age or education.
    All participants underwent a thorough clinical investigation 
including medical history, and physical, neurological and psychi-
atric examinations. Additionally, a neuropsychological examina-
tion was carried out by psychologists. Exclusion criteria for this 
study included psychiatric diseases (major depressive disorder ac-
cording to the DSM-III-R criteria, psychotic disorder, bipolar af-
fective disorder), chronic alcoholism, cerebral tumor, infection of 
the central nervous system, systemic diseases and diabetes mel-
litus. No participants on corticosteroid therapy were included. 
Reported use of medications potentially affecting hormone levels 
included oral estrogens (MCI: n = 5; controls: n = 7),   L -thyroxine 
(MCI: n = 3; controls: n = 2) and   -blockers (MCI: n = 2; controls: 
n = 3). The controls were members of senior citizen organizations 
or spouses of cognitively impaired subjects who had been assessed 
at the clinic. This is an extended sample from that reported on by 
Lind et al.   [14]  . All participants gave their informed consent to 
participate. The study was approved by the ethics committee for 
medical research at the University of Gothenburg.
  Diagnostic  Procedure 
  The diagnosis of MCI was made in accordance with recom-
mendations by the International Working Group on Mild Cogni-
tive Impairment   [31]  . The diagnostic procedure included a medi-
cal history (self-reported and medical record review) and assess-
ment of cognitive symptoms including: the cognitive variables 
13–20 of the Stepwise Comparative Status Analysis (STEP) cover-
ing memory disturbance, disorientation, impaired abstract 
thinking, impaired spatial functioning, poverty of language, ag-
nosia and apraxia  [32] ; I-Flex, a short form of the Executive Inter-
view   [33]  ; the MMSE   [34]  , and the Clinical Dementia Rating 
(CDR) scale  [35] . The CDR was based on information provided by 
the participant and a key informant. Basic criteria for the MCI 
diagnosis were subjective and objective anamnestic evidence of a 
progressive cognitive impairment for more than 6 months. In ad-
dition, cognitive symptoms according to STEP, I-Flex, MMSE or 
CDR protocols were required. Participants with more than 2 
symptoms on the STEP and/or a score below 24 on the MMSE 
were considered to fulfill the criteria for dementia and were there-
fore not included.
  Neuropsychological  Assessment 
  The neuropsychological battery included tests of speed and 
attention, learning and episodic memory, and visuospatial, lan-
guage and executive functions in agreement with the recommen-
dations by the American Academy of Neurology  [36] . The neuro-
psychological test battery has been described in detail   [30] .  The 
tests were administered in a standardized sequence and conduct-
ed in 2 sessions of 1–2 h. Verbal tests and nonverbal tests were 
alternated in each session. The test sequence was designed to min-  TH in MCI  Dement Geriatr Cogn Disord 2010;30:205–211 207
imize contamination on the memory tests. Thus, no test with con-
tent that could affect performance on a memory test was admin-
istered between immediate and delayed recall. 
 Serum  Samples 
 Fasting serum samples were drawn between 8 a.m. and 10 a.m. 
for measurement of total testosterone (TT), estradiol, IGF-1 and 
sex-hormone-binding globulin (SHBG). Nonfasting serum sam-
ples were drawn for measurements of thyroid-stimulating hor-
mone (TSH), total T  4   (TT 4 ),  fT 4   and total triiodothyronine (TT  3 ). 
All samples were transported immediately to the laboratory for 
biochemical analyses. TSH, TT  4 , fT 4  and TT  3  were analyzed using 
electrochemiluminescent immunoassays. TT and IGF-1 were de-
termined using immunochemical assays. Estradiol was deter-
mined using a radioimmunoassay, and for SHBG, a carbonylmet-
alloimmunoassay was used. All hormonal analyses were conduct-
ed at accredited hospital laboratories in Gothenburg, Sweden.
  Saliva  Samples 
  Saliva was collected by the participants at home, using 
Salivette    (Sarstedt Rommelsdorf, Germany)  [37]  over the course 
of 2 days. The participants received oral and written instructions 
including noting times of awakening, intake of lunch and saliva 
collection. The participants were asked to refrain from eating, 
brushing teeth, smoking or rinsing their mouths for at least 
30 min prior to sample collection (for a more detailed description, 
see  Lind  et  al.    [14] ).   On  day  1,   saliva samples were collected in 
the morning upon awakening, 15 min after awakening, and at 
noon, 4 p.m. and 8 p.m. At 10 p.m., 0.5 mg dexamethasone was 
administered orally. On day 2, saliva was collected according to 
the same protocol. Salivary cortisol levels were determined using 
SPECTRIA   .
  Statistical  Analyses   
  Means and SD were determined for continuous variables. 
Skewed variables were log transformed to approximate normal 
distributions. Continuous variables were compared using inde-
pendent sample t tests, and for skewed variables that could not be 
transformed, the nonparametric Mann-Whitney U test was uti-
lized. Logistic regression analyses estimating the odds of MCI 
were performed separately for each hormone: cortisol, testoster-
one, estradiol, IGF-1 and TH. Hierarchical multiple regression 
analyses were employed to evaluate multiple endocrine predictors 
of cognition. All regression models were adjusted for age, sex, 
body mass index, total cholesterol, high-density lipoprotein, low-
density lipoprotein, systolic and diastolic blood pressure, and use 
of medications such as   L -thyroxine,     -blockers and estrogens.
    Principal component analysis (PCA; SIMCA-P 10.0) was per-
formed on the data from the neuropsychological test battery pre-
sented in Eriksson et al.   [38]  . The significance of the model was 
determined by cross-validation. The PCA resulted in one signifi-
cant latent variable that summarized the constituent neuropsy-
chological test variables. The composite score of each subject was 
considered to express the general level of neuropsychological per-
formance. Group comparisons for the subsequent analysis were 
carried out by univariate ANOVA. For post hoc analyses, Tukey’s 
honestly significant difference was used. Results were considered 
significant at p   !   0.05. Correction for multiple comparisons has 
not been applied due to the preliminary nature of the data. SPSS 
version 13.0 was used for all statistical analyses.
  For further evaluation of cortisol, areas under the curve (AUC) 
with reference to 0 for each day were calculated to estimate the 
total cortisol secreted over the day (AUC  G  ). The formula for the 
AUC was derived from the trapezoid formula   [39] .  Additionally, 
mean values for both days were calculated, as well as mean values 
only for the wake-up response (wake-up + 15 min after wake-up 
divided by 2). The free androgen index (FAI) was computed (TT/
SHBG   !   100) as an indicator of testosterone not bound to SHBG 
  [9] .  TT 3 /fT 4    !   100 ratios were calculated to estimate the conver-
sion of fT  4   to TT  3    [40] .
  R e s u l t s  
  Demographics and Neuropsychological Assessment 
  Data from all 43 MCI cases and 26 healthy controls 
were analyzed. As presented in   table 1  , the controls were 
significantly older than the MCI group (p = 0.001). How-
ever, no significant differences were observed regarding 
years of education (p = 0.128) or general intellectual ca-
pacity (p = 0.538), as assessed by Raven’s Coloured Pro-
gressive Matrices. As indicated in   table 2  , the control 
group performed significantly better than the MCI group 
on 10 neuropsychological tests. 
    Of the MCI cases, 2 were considered pure amnestic 
MCI, 12 amnestic MCI multiple domain, 11 nonamnestic 
MCI multiple domain, and 17 nonamnestic MCI single 
domain. The PCA yielded one component accounting for 
34.2% of the variance, and the weighted average scores 
(PCA) of the MCI group were significantly lower com-
pared to the controls. 
    Endocrine Profile in MCI Cases versus Controls 
  The average levels of testosterone, FAI, estradiol, IGF-
1, TSH, TT  4 ,  fT 4   and TT  3   did not differ between MCI 
cases and controls, and between men and women. A mul-
tivariate logistic regression model estimating the odds of 
MCI by all 7 endocrine variables showed no relationships. 
The pre- and postdexamethasone cortisol awakening re-
sponse, including cortisol levels at awakening and 15 min 
after awakening, distinguished between MCI and con-
trols (   2  = 12.4; d.f. = 4; p = 0.015) with an overall correct 
prediction of 71.6%. An independent contribution was 
found for cortisol levels at 15 min after awakening on day 
2 after the dexamethasone test (Wald = 4.126; p = 0.041; 
OR = 4.538; 95% CI: 1.05–19.53).
    Relationship of Cortisol to Other Endocrine Axes  
 In the MCI group, positive correlations were found be-
tween fT  4   and basal mean salivary cortisol (r = 0.514; p = 
0.001), cortisol awakening response (r = 0.556; p  !  0.001),  Quinlan   /Nordlund   /Lind   /Gustafson   /
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AUC  G   (r = 0.361; p = 0.021) and cortisol awakening re-
sponse after the dexamethasone test (   = 0.359; p = 0.021) 
and AUC  GDex   (r = 0.355; p = 0.024). Similar associations 
were found for TT  4   levels (p   !   0.05). No associations be-
tween cortisol and other hormones were found in the 
control group.
    Endocrine Variables and Cognition 
 TT 3   levels were inversely associated with neuropsy-
chological tests of episodic memory, and of language, vi-
suospatial and executive function. Performance on neu-
ropsychological tests declined with TT  3   l e v e l s  a s  d i s -
played in  table 3 . TT  3  levels predicted 26% of the variance 
in the cognitive composite scores. No associations be-
tween TT  3  and cognitive variables were found in the con-
trol group. After exclusion of 3 MCI cases on   L -thyroxine 
treatment with TT  3   levels below the normal range, Rey 
Auditory Verbal Learning Test delayed recall (p = 0.062), 
the Boston Naming Test (p = 0.092), FAS word fluency 
(p = 0.134) and similarities (p = 0.100) did not reach sig-
nificance. The inverse association for these tests with TT  3  
remained. The inclusion of other endocrine variables did 
not improve the model to predict cognitive performance. 
    Stratification of the MCI cases by tertile of TT  3   levels 
(reference range: 1.3–3.1 nmol/l) revealed differences (p  1  
0.05) between the TT  3  groups in parallel serial mental op-
erations, Block design, FAS word fluency, and Assessment 
of Subtle Language Deficits repetition. Differences were 
also observed for the episodic memory test, Rey Auditory 
Verbal Learning Test delayed recall, learning, maximum 
number of words learned, and recognition. The high-TT  3  
group (TT  3    1  1.6 nmol/l) had a 44.3% rate of forgetting 
between the maximum number of words and delayed re-
call, compared to 29.7% in the normal-TT  3   group (TT  3   = 
1.4–1.6 nmol/l) and 23.1% in the low-TT  3  group (TT  3   ! 1.4 
nmol/l). No mean difference in cognitive function could 
be found comparing MCI cases with low TT  3  levels to nor-
mal controls (data not presented).
Table 1. C  haracteristics of MCI cases and controls: the Gothenburg MCI study
Controls M CI
male (n = 8) female (n = 18) total (n = 26) male (  n = 18) female (n = 25) total (n = 43)
Age, years 66.886.9 66.386.2 66.586.2 60.983.9 61.186.3 61.185.4
Education, years 11.582.1 11.182.4 11.282.3 12.483.6 12.683.7 12.683.7
MMSE score (0–30 points) 29.680.5 29.281.1 29.481.0 28.281.6 27.981.6 28.181.5
Raven’s CPM 30.383.1 32.182.7 31.083.5 32.383.3 30.483.5 31.682.9
Endocrine variables
Testosterone, nmol/l 14.283.0 1.180.6 5.386.5 16.585.3 1.080.6 7.588.5
FAI 41.589.7 2.381.6 14.9819.4 46.3816.1 1.082.3 20.7824.3
Estradiol, nmol/l 0.0680.02 0.0680.05 0.0680.04 0.0780.02 0.0580.02 0.0580.02
IGF-1, g/l 160.6839.5 147.2864.8 151.3857.7 157.2846.7 154.2855.9 155.7851.8
TSH, mIU/l 1.580.7 1.681.5 1.681.3 1.980.9 1.580.5 1.780.7
TT4, nmol/l 84.5814.4 92.2817.5 89.7816.7 81.8816.6 91.7817.3 87.6817.5
fT4, pmol/l 12.982.0 14.382.6 13.882.5 13.282.0 13.782.2 13.582.1
TT3, nmol/l 1.580.3 1.680.3 1.580.2 1.580.2 1.580.2 1.580.2
Cortisol
AUCG day 1 6,938.181,864.9 6,519.183,582.3 6,648.083,120.7 6,159.483,427.1 6,755.582,589.4 6,508.382,939.7
AUCG day 2 2,052.682,119.54 1,409.38877.7 1,596.981,340.7 1,514.58885.4 1,629.581,179.3 1,580.681,053.3
Awakening day 1, nmol/l 12.585.8 13.685.8 13.385.7 10.584.7 14.9810.3 13.188.5
Awakening 15 min day 1, nmol/l 16.586.2 18.485.8 17.885.9 15.587.1 21.4810.9 19.089.8
Awakening day 2, nmol/l 2.381.9 1.680.9 1.881.3 1.480.9 2.282.4 1.981.9
Awakening 15 min day 2, nmol/l 2.081.7 1.380.5 1.581.0 2.282.5 2.983.9 2.583.4
Somatic variables
BMI score 26.982.9 25.183.0 25.783.0 24.783.1 24.383.8 24.483.5
Total cholesterol, mmol/l 6.081.9 5.681.2 5.781.4 5.280.7 6.181.2 5.781.1
HDL, mmol/l 1.580.4 2.080.5 1.880.5 1.680.4 2.080.5 1.880.6
LDL, mmol/l 4.482.1 2.981.1 3.381.5 3.080.7 3.681.3 3.481.1
Systolic blood pressure, mm Hg 140.6816.8 137.0821.3 138.2819.7 131.7817.7 142.6823.6 138.1821.8
Diastolic blood pressure, mm Hg 78.5813.1 77.288.7 77.6810.0   79.3810.6 82.589.5 81.2810.0
Valu  es denote means 8 SD. Between the groups, there were differences in age and MMSE scores (p < 0.001). No differences in endocrine and somatic 
variables were observed (p < 0.05).
Raven’s CPM = Raven’s Coloured Progressive Matrices; BMI = body mass index; HDL = high-density lipoprotein; LDL = low-density lipoprotein.  TH in MCI  Dement Geriatr Cogn Disord 2010;30:205–211 209
  Discussion 
 To our knowledge this is the first study to report an in-
verse association of serum TT  3   levels with cognitive func-
tion in MCI. While MCI cases with high TT  3  levels within 
the normal range showed more cognitive impairment in 
episodic memory, language and executive function, MCI 
cases with TT  3  levels at or below the lower boundary of the 
normal range were comparable with healthy controls. No 
association between TT  3   and cognition was found in the 
control group. It may be that circulating TT  3   is related to 
cognitive impairment under the compromising condition 
of MCI. Compared to healthy controls, higher measure-
ments of AD pathology   [41]   and brain atrophy   [42]   have 
been observed in MCI, which may, in combination with 
higher TT  3 , decrease cognitive function. This may explain 
why the association was specific to the MCI group. The 
lack of differences in TH   between MCI and controls sug-
gests that cognitive impairment is not due to thyroid dis-
ease or reduced levels of TH. Conversely, optimal TH lev-
els may shift in MCI to lower ranges.
    Potential direct action of T  3   on cognition and demen-
tia pathology has been discussed. Aggravation of the cho-
linergic deficit and associated cognitive dysfunction ob-
served in AD has been suggested due to TH-induced de-
pletion of acetylcholine   [10]  . TH-induced oxidative 
damage and simultaneously reduced antioxidative de-
fense enzyme levels may also increase neurodegeneration 
  [43]  . The interpretation of our findings is difficult since 
serum concentrations of TH do not accurately reflect TH 
metabolism in the central nervous system. With the oc-
currence of hippocampal and cortical atrophy in MCI 
and dementia, a normal concentration of peripheral TH 
entering the brain may become toxic under the condition 
Table 2. S elected neuropsychological test scores for MCI cases and 
controls: the Gothenburg MCI study
Controls MCI p
Speed and attention
Trail Making Test A, s 34.488.3 40.8812.6 0.026
Digit Symbol 50.587.7 43.9810.2 0.007
Memory
RAVLT delayed recall 9.382.3 7.582.8 0.018
WLM delayed recall 21.984.8 17.987.9 0.013
Visuospatial function
VOSP silhouettes 22.082.6 21.183.7 0.264
Block design 27.4887.9 25.7810.2 0.455
Language
Token Test 21.181.0 20.281.6 0.014
Boston Naming Test 54.984.8 53.184.1 0.032
Executive function
Stroop test, s 24.585.3 31.5810.8 0.001
PaSMO, s 61.8823.2 84.0831.1 0.002
Cognitive estimation test 3.081.6 4.081.9 0.047
Cognitive weighted averages 
(PCA) 1.281.5 –0.582.5 0.001
V  alues denote means 8 SD unless specified otherwise.
RAVLT = Rey Auditory Verbal Learning Test; WLM = 
Wechsler logical memory; VOSP = Visual Object and Space Per-
ception; PaSMO = parallel serial mental operations.
Table 3. U  nivariate linear regression models predicting cognitive 
test scores by TT3: the Gothenburg MCI study
 p 95% CI
Speed and attention
Digit Symbol –0.220 0.157 –26.5; 4.4
Trail Making Test A, s 0.254 0.100 –3.2; 35.7
Trail Making Test B, s 0.381 0.012 22.2; 167.6
Digit span forward –0.189 0.225 –2.7; 0.7
Digit span backward –0.356 0.019 –3.5; –0.3
Memory and learning
RAVLT delayed recall –0.397 0.008 –12.7; –2.0
RAVLT recognition –0.342 0.029 –5.1; –0.3
RAVLT max –0.437 0.004 –8.5; –1.7
WLM delayed recall –0.055 0.734 –14.7; 10.4
RCF delayed recall –0.219 0.158 –17.2; 2.9
Visuospatial function
RCF copy –0.271 0.079 –10.9; 0.6
VOSP silhouettes –0.165 0.291 –8.3; 2.5
Block design –0.494 0.001 –37.2; –10.6
Language 
Token Test –0.231 0.136 –4.3; 0.6
Boston Naming Test –0.318 0.038 –11.9; –0.3
FAS word fluency –0.385 0.011 –51.5; –7.1
Similarities –0.358 0.019 –10.6; –1.0
ASLD repetition –0.500 0.001 –22.0; –6.3
Executive function
PaSMO, s 0.384 0.012 16.2; 124.5
Dual Task (t-score) –0.097 0.540 –17.3; 9.2
WCST –0.352 0.052 –39.5; 0.2
Stroop test, s 0.164 0.306 –8.6; 26.6
Cognite estimation task 0.216 0.174 –0.9; 4.8
Cognitive weighted averages 
(PCA) –0.509 0.001 –10.5; –3.1
R  AVLT = Rey Auditory Verbal Learning Test; WLM = 
Wechsler logical memory; VOSP = Visual Object and Space Per-
ception; ASLD = Assessment of Subtle Language Deficits repeti-
tion; FAS = verbal fluency test (number of words beginning with 
F, A and S); PaSMO = parallel serial mental operations; WCST = 
Wisconsin Card Sorting Test (computer version). Quinlan   /Nordlund   /Lind   /Gustafson   /
Edman    /Wallin    
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of an altered ratio of TH-sensitive neurons to TH. In-
creased CSF levels of rT  3   and decreased TT  3   have been 
observed in AD compared to healthy controls, which may 
reflect a relative excess of TH in the brain since corre-
sponding serum TH levels were not altered  [44] . The hip-
pocampus is remarkably sensitive to T  3  , and relative ex-
cess may manifest in aggravated episodic memory im-
pairment.
    Despite a higher cortisol awakening response after a 
dexamethasone load in the MCI group, cortisol was not 
related to impaired cognitive function in MCI. Other 
hormones were not related to cognition as well. The effect 
of cortisol on cognition is well studied. The lack of asso-
ciation in this study may be due to the cross-sectional 
design. The effect of higher cortisol levels on cognition 
may be only observable over time in relationship to great-
er cognitive decline, rather than in cross-sectional asso-
ciations with neuropsychological test scores   [45]  . It has 
also been reported that age-related increases in cortisol 
levels are not uniformly observed. In some people they 
increase and in others they remain stable in relationship 
to age   [11]  , which may obscure a potential association 
with cortisol in this study. All participants in this study 
were considered healthy according to endocrine markers. 
A positive effect on cognition as shown by some hormone 
supplementation studies   [25]   may only be detectable in 
MCI cases with low hormone levels at baseline, followed 
by pharmacologically increased levels.
    While our data point to some new findings relating 
TH to cognition in MCI, limitations need to be discussed. 
Our sample size is small and requires replication. The use 
of a comprehensive neuropsychological test battery and a 
comprehensive panel of endocrine markers with subse-
quent multiple comparisons may lead to familywise type 
I error and false-positive findings. Due to the explorative 
nature of this study, we did not correct for multiple com-
parisons. Analyses of the association of TT  3   with cogni-
tive function included three MCI cases on   L -thyroxine 
treatment. All three cases had normal TSH and fT  4 ,  but 
low TT  3   values. Upon exclusion of these cases, four neu-
ropsychological tests, mainly assessing language, did not 
reach significance, but the results remained similar in es-
sential aspects. Although this may point to a specific role 
for circulating TT  3   levels, a potential bias due to thyroid 
disease and treatment should not be excluded.
    In conclusion, serum TT  3   was inversely associated 
with cognitive function in MCI, such that those cases 
with TT  3  levels at or below the lower boundary of the ref-
erence range performed better on neuropsychological 
tests. While the mechanisms remain unclear, optimal 
levels of TH under a compromising and potentially pro-
gressive condition such as MCI and related neuropathol-
ogy need reconsideration.
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